Pro-Dex, Inc.

NASDAQ:PDEX

Medical - Instruments & Supplies

Healthcare
$63.94 +5.86%

+$3.54 today

Market cap
$204.61M
Beta
-0.00
P/E (TTM)
17.1
EPS (TTM)
$3.75
52W Low $23.47High $68.99

Volume 0.04M

Average 0.04M

PDEX Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Pro-Dex, Inc.NASDAQ: PDEX

Net Margin · Q3 FY2026 · quarter ended Mar 2026

Net margin widens to 19.7%

Net margin was 19.7% in Q3 FY2026, up 0.9 pp from a year earlier. On a trailing-twelve-month basis it was 16.1%, up 1.5 pp year over year. Over 3 fiscal years it widened by 2.6 pp.

Context

  • Net margin widened in 2 of the last 3 fiscal years.

What to watch

Whether net margin reaches the consensus estimate from 1 analysts of 17.1% for the fiscal year ending Jun 2026, up from 13.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
19.7%+8.0 pp QoQ
Last fiscal yearJun 2025
13.5%+9.5 pp YoY
LTMMar 2026
16.1%+1.5 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.9 pp+4.7 pp+3.8 pp
1 year+9.5 pp+3.6 pp-5.9 pp
3 years+2.6 pp-0.4 pp-3.0 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
13.5%
Year-over-year change
+9.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How PDEX compares with its peers on the latest reported figures

  • PDEX's LTM Mar 2026 net margin of 16.1% is the highest of the 7 companies compared; the peer median is -7206.0%.
  • Its year-over-year change of +1.5 pp is the 4th highest of 5, against a peer median of +15.7 pp.
  • Over three fiscal years its change of +2.6 pp compares with a peer median of +122.7 pp.
PDEX Competitors Peer median
Net Margin for PDEX and competitors
Company Period LTM level YoY 3-year change
PDEXPro-Dex, Inc.LTM Mar 202616.1% +1.5 pp+2.6 pp
APYXApyx Medical CorporationLTM Mar 2026-16.4% +26.0 pp+30.9 pp
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026-145.8% +5.4 pp+214.6 pp
LUCDLucid Diagnostics Inc.LTM Mar 2026-876.7% +604.8 pp+13666.8 pp
MBOTMicrobot Medical Inc.LTM Mar 2026-13535.2% ——
SERASera Prognostics, Inc.LTM Mar 2026-56386.0% -27700.7 pp-22930.0 pp
STSSSkyAI, Inc.LTM Mar 2026-93391.3% ——
GLSIGreenwich LifeSciences, Inc.FY2025— ——
CGTXCognition Therapeutics, Inc.FY2025— ——
Peer median (excluding PDEX) -7206.0%+15.7 pp+122.7 pp

Competitors are the stored peer set for PDEX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue42.04M42.04M46.09M53.84M66.59M
Cost of Revenue28.91M28.91M33.34M39.29M47.08M
Gross Profit13.13M13.13M12.75M14.55M19.51M
Gross Margin31.2%31.2%27.7%27.0%29.3%
Research & Development2.98M2.98M2.8M3.19M3.64M
Selling, General & Admin4.99M4.99M4.18M4.19M5.19M
Operating Expenses8.01M8.01M6.99M7.38M8.82M
Depreciation & Amortization726K726K857K1.16M1.24M
EBITDA6.88M6.88M10.82M4.35M14.13M
EBITDA Margin16.4%16.4%23.5%8.1%21.2%
Operating Income5.12M5.12M5.76M7.17M10.69M
Operating Margin12.2%12.2%12.5%13.3%16.1%
Interest Income126K76K294K144K82K
Interest Expense352K464K533K558K829K
Other Income / Expenses571K571K3.67M(4.54M)1.37M
Income Before Tax5.69M5.69M9.43M2.63M12.06M
Pre-Tax Margin13.5%13.5%20.5%4.9%18.1%
Income Tax Expense1.12M1.12M2.35M507K3.08M
Net Income4.57M4.57M7.07M2.13M8.98M
Net Margin10.9%10.9%15.3%4.0%13.5%
EPS (Basic)1.171.261.980.612.73
EPS (Diluted)1.131.211.950.602.67
Weighted Avg Shares3.8M3.64M3.57M3.5M3.29M
Weighted Avg Shares (Diluted)3.94M3.76M3.64M3.57M3.36M

Pro-Dex, Inc.

NASDAQ:PDEX

Intrinsic Alpha fair value

Locked

Current Price

$63.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.